Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Nemtabrutinib?
Nemtabrutinib is a small molecule commercialized by Merck, with a leading Phase III program in Relapsed Chronic Lymphocytic Leukemia (CLL);Refractory...
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Nemtabrutinib?
Nemtabrutinib is a small molecule commercialized by Merck, with a leading Phase III program in Chronic Lymphocytic Leukemia (CLL). According...